1. Pang Y, Bai G, Zhao J, Wei X, Li R, Li J, Hu S, Peng L, Liu P, Mao H. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer. J Transl Med. 2022;20:336.
2. Lin Q, Ma X, Hu S, Li R, Wei X, Han B, Ma Y, Liu P, Pang Y. Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma. Cancer Manag Res. 2021;13:1955-1965.
3. Ma X, Lin Q, Cui G, Zhao J, Wei X, Li R, Mao H, Ma Y, Liu P, Pang Y. GABPA Expression in Endometrial Carcinoma: A Prognostic Marker. Dis Markers. 2021;2021:5552614.
4. Peng LU, Bai G, Pang Y. Roles of NPAS2 in circadian rhythm and disease. Acta Biochim Biophys Sin (Shanghai). 2021;53:1257-1265.
5. Lu G, Lu T, Pan J, Guo L, Pang Y, Liu P. Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis. Arch Gynecol Obstet. 2021;303:1569-1579.
6. Pang Y, Yuan H, Ren A, Zhang S, Liu P. Primary malignant melanoma of the female genital tract synchronously involving the vulva and uterine cervix: A case report. Medicine (Baltimore). 2019;98:e16366.
7. Pang Y, Si M, Sun B, Niu L, Xu X, Lu T, Yuan H, Lou H. DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway. Food Chem Toxicol. 2014;69:163-174.
8. Pang Y, Mao H, Shen L, Zhao Z, Liu R, Liu P. MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP. Onco Targets Ther. 2014;7:587-597.
9. Dong R, Pang Y, Mao H, Yang N, Liu P. Successful pregnancy following conservative management of low-grade endometrial stromal sarcoma: A case report. Oncol Lett. 2014;7:1039-1042.
10. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai). 2010;42:363-369.